Navigation Links
Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
Date:11/1/2013

PALO ALTO, Calif., Nov. 1, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG) is pleased to announce that it has treated the final patient of its Phase I/IIa clinical trial for ReJoin™, a human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA). The trial tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce inflammation and repair damaged joint cartilage.

The clinical trial is conducted by Shanghai's Renji Hospital, a tertiary hospital affiliated with Shanghai Jiao Tong University School of Medicine. As previously reported, the interim analysis of the trial demonstrated that patients had a clinically meaningful reduction in pain and increase in mobility, with a significant improvement (P<0.05) from the baseline in clinical scores for SF-36, NRS-11, and WOMAC osteoarthritis indices, and no serious adverse events were reported for the duration of the trial.

Full data analysis by FuDan Medical University Department of Biostatistics will be carried out in the next four to six weeks and the final report of the trial will be announced before the end of the year.

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers.  Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Contact:

Sarah Kelly 
Director of Corporate Communications, CBMG
+1 650 566 5064
sarah.kelly@CellBioMedGroup.com


'/>"/>
SOURCE Cellular Biomedicine Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cellular Biomedicine Group Announces New Product Approved for Market in China and New Exclusive License
2. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
3. Decellularized mouse heart beats again after regenerating with human heart precursor cells
4. Cellular Dynamics International Announces Launch of Initial Public Offering
5. Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market
6. Cellular Therapy and Cord Blood 2013 Market Report
7. Cellular Biomedicine Group Announces Appointment of Corporate Controller
8. Cellular Dynamics International Expands MyCell Products Line with Disease Models, Genetic Engineering Patents
9. Cellular Dynamics International Files Registration Statement for Proposed Initial Public Offering
10. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
11. Intra-Cellular Therapies Appoints Professor Sir Michael Rawlins to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , Jan. 23, 2017  Recognizing the need ... scientific discovery and solutions, the University of Miami ... Institutes for Science and Engineering to achieve those ... (STEM) to help solve some of the world,s ... President Julio Frenk unveiled the network ...
(Date:1/24/2017)... - BioAmber Inc. (NYSE: BIOA ) today announced ... Rodman & Renshaw, a unit of H.C. Wainwright ... representative of several underwriters, under which the underwriters have ... minimum of 2,105,264 shares of common stock of the ... 1,052,632 shares of common stock of the Company with ...
(Date:1/23/2017)... CALGARY , Jan. 23, 2017 /PRNewswire/ - Resverlogix ... preliminary results from the New Zealand ... impaired patients. The data showed remarkable results in reducing ... versus healthy control patients. It is believed that this ... direct connection of this type can be made between ...
(Date:1/23/2017)... ... January 23, 2017 , ... AxioMed ... Neurosciences Symposium (CANS) annual meeting in Montego Bay, Jamaica from January 26-28th. “We’re ... hands-on workshop for surgeons to experience the simplicity of the surgical technique,” said ...
Breaking Biology Technology:
(Date:1/18/2017)... 18, 2017  In vitro diagnostic (IVD) companies were ... acquisitions (M&A), and Kalorama Information expects that trend to ... been shifting. Generally, uncertainty in reimbursement and healthcare reform ... has changed the acquisitions landscape. Instead of looking to ... buying partners outside of their home country and also ...
(Date:1/13/2017)... PORT WASHINGTON, N.Y. , Jan. 13, 2017 ... provider of technology solutions for the homecare industry, ... appointment of homecare industry expert, Justin Jugs, as ... Justin brings more than 15 years of homecare ... the team in developing strategic plans to align ...
(Date:1/12/2017)... 2017  New research undertaken by Fit Small Business ... 1,000 participants were simply asked which office technology had they ... consider standard issue.  Insights on what will be ... from futurists and industry leaders including Penelope Trunk , ... Some of these findings included; ...
Breaking Biology News(10 mins):